drugset / Trial / NCT05105607
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of D-4517.2 after single subcutaneous (SC) doses in healthy participants.
Timeline
- Start
- 2022-01-11
- Primary completion
- 2022-08-31
- Completion
- 2022-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Migaldendranib | Small molecule | 0.25 mg/kg | Subcutaneous |
| Subject | Migaldendranib | Small molecule | 0.5 mg/kg | Subcutaneous |
| Subject | Migaldendranib | Small molecule | 1 mg/kg | Subcutaneous |
| Subject | Migaldendranib | Small molecule | 2 mg/kg | Subcutaneous |